BridgeBio Pharma Inc.
BridgeBio Launches Convertible Senior Notes Offering and Repays Existing Debt
Summary
BridgeBio Pharma, Inc. issued $575 million of 1.75% Convertible Senior Notes due 2031, using the proceeds to repay all outstanding borrowings under its Financing Agreement and repurchase shares of its common stock. The Notes can be converted into cash, common stock, or a combination thereof at BridgeBio's election. The termination of the Financing Agreement provides the company with reduced interest expense and greater operational flexibility.
Profitelligence Alerts
Get alerts for BBIO
Be first to know when BridgeBio Pharma Inc. files with the SEC.
Filing Categories
Exhibits (3)
Advertisement
About BridgeBio Pharma Inc.
BridgeBio Pharma Inc. is a cutting-edge biotechnology company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases. The company's primary purpose is to bridge the gap in medical research and bring breakthrough therapies to those with rare and often overlooked genetic disorders. By utilizing a targeted approach, BridgeBio Pharma Inc. works across multiple sectors including dermatology, oncology, cardiology, neurology, and endocrinology. The company partners with academic institutions, research organizations, and industry leaders to harness the latest scientific advancements in genomics and biotechnology. Established with a mission to translate genetic research into real-world medical solutions, BridgeBio Pharma Inc. plays a significant role in the biopharmaceutical market. It is heavily involved in the early and late stages of drug development, positioning itself as a key player in the quest to address unmet medical needs. This focus on genetic-centric therapies underlines its importance in the rapidly evolving landscape of biotechnology and personalized medicine.
Official SEC Documents
Advertisement